Search

Displaying results 2101 - 2110 of 10000 in total
  1. Indication

    Coccidioidomycosis

    go.drugbank.com/conditions/DBCOND0000138
    Drugs: Amphotericin B · Fluconazole · Ketoconazole · Posaconazole · Voriconazole
    Synonyms: San Joaquin valley fever
  2. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

  3. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    [A222078] The chief surface target of EBOV particles is the GP<sub>1,2</sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic … INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  4. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    Alpelisib was granted FDA approval on 24 May 2019. … [L6652] In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.[L41384]

  5. Drug

    Vestronidase alfa

    go.drugbank.com/drugs/DB12366
    ApprovedInvestigational

    MPS VII is a progressive condition that affects most tissues and organs due to the lack of a lysosomal enzyme called beta-glucuronidase, leading to buildup of toxic metabolites. … Vestronidase alfa was FDA-approved on November 17th, 2017 under the trade name Mepsevii as an intravenous infusion for the treatment of pediatric and adult patients.

  6. Drug

    Sasanlimab

    go.drugbank.com/drugs/DB18849
    Investigational

    Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).

  7. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

    Synonyms: 5-chloro-7-iodoquinolin-8-olMixtures: CORTINOL D, Phenoris Ont
  8. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … [A243764, A243769, A243774] As existing asthma treatments such as [omalizumab], [mepolizumab], [reslizumab], [benralizumab], and [dupilumab] act on specific downstream mediators of the inflammatory response

  9. Drug

    Agalsidase alfa

    go.drugbank.com/drugs/DB15874
    ApprovedInvestigational

    [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413] … [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.

    Synonyms: alpha-D-galactosidase, alpha-D-galactopyranosidase
  10. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. … [L41900] It is used as monotherapy or in combination with other drugs, such as corticosteroids.

    Products: Dupixent 300 mg Solution for Injection in Pre-filled Syringe, Dupixent 200mg Solution for Injection in Pre-Filled Syringe